This shift marks a departure from the stability usually associated with health-care holdings. As traders chase volatility, evergreen companies are losing their appeal, leaving defensive names to settle in flat or negative territory.
Amid this broader market recalibration, Ipsen is doubling down on its growth strategy. The French pharmaceutical firm has moved to acquire Kartos Therapeutics in a transaction valued at up to $1.75 billion, a strategic play aimed at fortifying its oncology pipeline despite the cooling interest in conservative health-care assets.
Comments (0)
No comments yet. Be the first!